ReviewSub-cellular biochemistry2025
Reactive Microglia and Astrocytes as Therapeutic Targets in Prion Diseases.
Review in Sub-cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Prion diseases, also known as transmissible spongiform encephalopathies, are a group of fatal, transmissible neurodegenerative disorders affecting both humans and animals, with no available therapeutic treatments. Recent research highlights the critical involvement of reactive microglia and astrocytes in the pathogenesis of these diseases. This chapter will review emerging evidence on the harmful roles of reactive microglia and astrocytes in prion disease progression and explore potential therapeutic strategies aimed at targeting their reactive states. A particular focus will be on the therapeutic potential of modulating microglial phagocytic activity and its associated pathways. We will address the challenges in designing effective therapies, including the phenotypic diversity of glial cells, regional differences in brain strain tropism, intercellular communication between microglia and astrocytes, dynamic changes in microglial role throughout disease progression, and the identification of optimal intervention windows. Finally, we will consider the possibility that different mechanisms underlie neurodegeneration across prion strains and Creutzfeldt-Jakob disease (CJD) subtypes, highlighting the importance of developing combination therapies targeting multiple pathways.
Indexed as
Identifiers
41004058What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.